VA GLP-1 Access Statistics, Cost, Coverage and Eligibility

Who may qualify through VA

For chronic weight management, the April 2026 VA Criteria for Use for Wegovy and Zepbound generally require a body mass index, or BMI, of at least 27 kilograms per square meter and at least one weight-related condition. BMI combines height and weight. A BMI of 27 is therefore not a stand-alone approval rule. Qualifying conditions can include high blood pressure, type 2 diabetes, unhealthy cholesterol or triglyceride levels, obstructive sleep apnea, osteoarthritis, metabolic syndrome or metabolic dysfunction-associated steatotic liver disease. The condition needs to be documented and relevant to the person's care. VA also requires documented participation in a comprehensive lifestyle intervention covering nutrition, physical activity and behavioral change. MOVE! is a common VA option. Comparable community programs may count when they meet those elements, but the care team needs to determine how participation is documented. The criteria also contain safety exclusions and situations needing closer review. Examples include pregnancy or breastfeeding, a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, severe delayed stomach emptying and some pancreatitis histories. These checks help determine whether a medicine is suitable; they are not a judgment about effort or need.

What a VA prescription may cost

VA's 2026 general Tier 3 brand-name outpatient prescription copay is $11 for up to 30 days, $22 for 31 to 60 days and $33 for 61 to 90 days. Those figures are benefit copays, not the medicine's cash price. A particular fill may follow a different schedule, so it is worth confirming the actual quantity and charge with the pharmacy. Some Veterans pay no medication copay. Priority Group 1 Veterans do not pay medication copays, and the annual medication copay cap is $700 for Priority Groups 2 through 8. Service connection, priority group, income and other benefit status can change the personal amount. VA does not publish its negotiated net price for semaglutide or tirzepatide. It also does not publish a current national GLP-1 spending total. That makes a precise VA-versus-commercial price comparison impossible from public records. Medicare GLP-1 Bridge began on July 1, 2026. Eligible Medicare Part D beneficiaries may obtain specified medicines for $50 per month through December 31, 2027. It is separate from VHA pharmacy benefits and does not change VA formulary criteria or VA copays.

Use is substantial and access varies

A National Bureau of Economic Research working paper estimated that more than 250,000 Veterans were receiving any GLP-1 medicine by the end of 2024. That is a broad utilization estimate. It includes treatment for type 2 diabetes and other approved uses, so it is not a count of Veterans receiving Wegovy or Zepbound for weight management. The Veterans Health Administration serves about 9.1 million Veterans each year through VA facilities and community care providers. The quarter-million figure therefore cannot tell a Veteran how likely approval will be, how long a local review will take or whether refills will be uninterrupted. Published VA research does show differences by care location. Across 130 VA facilities, semaglutide prescribing ranged from 0.4% to 11.7%. Another national analysis found a 1.2 percentage-point higher adjusted probability of GLP-1 prescribing among Veterans receiving VA-direct primary care than among those receiving mostly community primary care. Those studies do not establish why each difference occurred. They do show why it can help to ask a local team for the applicable Criteria for Use, whether a weight-management or pharmacy review is needed, and what records are missing.

What weight-loss results can mean

Trial averages can help set expectations, but they cannot predict an individual's result. They come from people with particular eligibility rules, follow-up schedules and lifestyle support. A real-world clinic result often looks different because people have other conditions, interruptions and ordinary day-to-day constraints. In STEP 1, a randomized trial of adults without diabetes, semaglutide 2.4 milligrams produced an average 14.9% weight reduction at 68 weeks, compared with 2.4% with placebo. At a starting weight of 250 pounds, 14.9% is about 37 pounds. FDA reported that tirzepatide 15 milligrams produced an average 18% weight reduction at 72 weeks in a larger trial of adults without diabetes. That is about 45 pounds from 250 pounds. In a trial involving people with type 2 diabetes, the FDA reported a lower average of 12%, showing why diabetes status and study population matter. A retrospective VA clinic study of 201 Veterans using semaglutide alongside nutrition counseling and exercise support found average weight loss of 10.0%, or 11.5 kilograms, after 12 months. For 250 pounds, that is about 25 pounds. The gap from major trials does not mean treatment failed. It reflects a shorter timeframe and care outside a tightly controlled trial.

Staying on treatment and handling side effects

Weight management with these medicines is commonly a long-term care question. VA's clinician guide notes that medication benefit often plateaus around six to nine months and that stopping obesity medication can lead to weight regain. Before starting, it is reasonable to discuss refill continuity, follow-up and what the plan would be if the medicine helps, does not help or becomes hard to tolerate. Common effects listed in product information include nausea, diarrhea, vomiting, constipation, stomach pain, fatigue and injection-site reactions. People can also need review for pancreatitis, gallbladder disease, dehydration-related kidney injury, low blood sugar when combined with certain diabetes medicines and diabetic-retinopathy complications in people with type 2 diabetes. FDA's 2026 review found no increased risk of suicidal thoughts or behavior across 91 placebo-controlled trials involving 107,910 participants. That finding does not replace personal care. New or worsening depression, unusual mood changes or thoughts of self-harm need prompt clinical attention. Compounded GLP-1 products are not FDA-approved. FDA says they should generally be used only when a patient's medical need cannot be met by an approved drug. A person considering one because VA access is uncertain should discuss the product, source, storage and medical history with a clinician and pharmacist first.

Questions to bring to a VA appointment

Bring an accurate height and current weight, a list of weight-related conditions and a complete medication list. Mention sleep apnea treatment, blood-pressure medicines, diabetes medicines, cholesterol treatment, joint pain, liver disease, gallbladder problems and any pancreatitis history. That information helps the team identify both an access route and safety concerns. Ask whether the appointment is addressing diabetes treatment, chronic weight management or another FDA-approved use. Ask how lifestyle-program participation is documented, which Criteria for Use applies, whether another review is needed and what follow-up is expected. The pharmacy questions are practical: What would my copay be for this prescription and fill quantity? How do refills, mail delivery, travel and a missed dose get handled? What symptoms should prompt a call? Tracking a weekly weight trend, hydration, bowel changes, side effects and other measures requested by the care team can make those conversations more specific.